Objective: Endoscopic step-up strategies for necrotizing pancreatitis are poorly documented in multidisciplinary real-world clinical practice. This study evaluated the feasibility and clinical outcomes of an endoscopic management strategy within a structured multidisciplinary framework for patients with necrotizing pancreatitis. Methods: This retrospective, single-center study evaluated 13 consecutive patients with necrotizing pancreatitis who underwent endoscopic treatment between January 2022 and December 2025. Demographic characteristics, disease severity via the Modified Computed Tomography Severity Index (MCTSI), details of endoscopic interventions, microbiological findings, and clinical outcomes were analyzed. Results: The median disease severity score was 8 (range, 4–10). Patients underwent a median of 6 (range, 2–15) endoscopic interventions, with the initial intervention performed at a median of 18 days (range, 1–90) from diagnosis. The median follow-up duration was 7 months (range, 1–41). Lumen-apposing metal stents followed by coaxial plastic pigtail stents were utilized in most patients. Microbiological cultures predominantly revealed Candida spp. and Klebsiella pneumoniae, including multidrug-resistant organisms in a subset. The median hospital stay was 21 days (range, 8–97), and the median intensive care unit (ICU) stay was 0 days (range, 0–44). No in-hospital mortality was observed; long-term complications occurred in a minority of patients. Conclusions: Endoscopic management within a structured multidisciplinary framework is a feasible and safe treatment strategy for necrotizing pancreatitis. Given the limited sample size, larger prospective studies are warranted to validate these findings.
Objective: Postoperative follow-up and treatment decisions after pancreatic cancer surgery are routinely determined by multidisciplinary tumor boards (MDTs), which represent the mainstay of clinical decision-making in these patients. However, this process is associated with increased workload, time consumption, and financial burden. Previous studies have demonstrated improved treatment planning, guideline adherence, and patient outcomes with MDTs, albeit with substantial time, cost, and administrative demands. The present study aims to compare MDT-based decision-making with an artificial intelligence (AI)–assisted model in the postoperative management of patients undergoing surgery for pancreatic cancer and to explore the potential utility of such a model. Materials and methods: An AI-based model was developed using clinical data from 67 patients discussed in multidisciplinary tumor boards between October 2020 and December 2023, in conjunction with current treatment guidelines. The model's recommendations were subsequently compared with MDT decisions in an independent cohort of 15 patients who underwent surgery in 2024. Results: The overall concordance rate between AI-generated recommendations and MDT decisions was 80%. The Cohen's kappa coefficient was 0.625 (95% CI: 0.278–0.972), indicating moderate agreement beyond chance. Three discrepant cases were further analyzed to explore potential reasons for discordance. Discussion: The findings suggest that AI-assisted decision-support systems may approximate MDT recommendations in postoperative pancreatic cancer management. However, observed discrepancies highlight the continued importance of expert clinical judgment and contextual interpretation in complex decision-making scenarios. Conclusion: AI-based models may serve as supportive tools in postoperative clinical decision-making by potentially reducing workload and time burden, but should complement rather than replace multidisciplinary expert evaluation.